Navigation Links
Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery

SEATTLE, Dec. 9 /PRNewswire/ -- Omeros Corporation today announced favorable results from a Phase 1 vehicle-controlled study of OMS201, another of Omeros' PharmacoSurgery(TM) product candidates, for use during urological surgery.

The Phase 1 study of OMS201 enrolled patients undergoing endoscopic removal of urinary stones, and was designed to evaluate the systemic absorption and safety of the drug product. The pharmacokinetic data from this study show that systemic plasma levels of the active agents of OMS201 in patients were minimal and in most cases below the level of quantification. There were no serious adverse events.

"We continue to be encouraged by the progress being made in our OMS201 development program, and the completion of this study represents another successful milestone as we advance our PharmacoSurgery(TM) platform," stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. "Based on these positive results, we intend to initiate a Phase 1/Phase 2 study evaluating the safety and preliminary efficacy of two higher concentrations of OMS201 in uroendoscopic surgery."

The Phase 1 study was a randomized, double-blind, vehicle-controlled and parallel-assigned study designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros' proprietary PharmacoSurgeryTM platform, is designed for use during urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minimally invasive prostate procedures. Added to standard irrigation solutions in urological surgery, OMS201 is delivered during the operation directly to the surgical site to inhibit surgically induced inflammation, pain and smooth muscle spasm.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgeryTM platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgeryTM clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. For more information on Omeros, visit the Company's Web site at

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Omeros and BlueCrest Announce $20 Million Debt Facility
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. Omeros Appoints David A. Mann to its Board of Directors
4. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
5. Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
6. Genomic Health Announces Appointment of Ginger Graham to Board of Directors
7. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
8. Elsevier Announces Winners of 3rd Annual Scopus Young Indian Scientist Award
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
10. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
11. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
Post Your Comments:
(Date:11/30/2015)...  HUYA Bioscience International, the leader in accelerating global ... today announced it has signed a Memorandum of Understanding ... collaboration between KDDF and HUYA with the ultimate goal ... for the global market. China,s ... innovative preclinical and clinical stage compounds. The company advances ...
(Date:11/30/2015)... San Jose, CA (PRWEB) , ... ... ... the Content Intelligence Company, today announced tighter software integration with MarkLogic, the ... management where organizations maximize information to drive change. , Smartlogic’s Content Intelligence ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):